This was the stock's second consecutive day of gains.
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
5h
Zacks.com on MSNWhy the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained TodayVertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close.
2h
Chalkbeat on MSNLinda McMahon’s first official K-12 visit: A Bronx charter schoolU.S. Education Secretary Linda McMahon took a tour of Vertex Partnership Academies founded by Ian Rowe, a senior fellow at ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...
CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results